Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

ImmuCell Corporation

ICCC
Current price
5.50 USD -0.05 USD (-0.90%)
Last closed 5.38 USD
ISIN US4525253062
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 49 404 408 USD
Yield for 12 month +9.34 %
1Y
3Y
5Y
10Y
15Y
ICCC
21.11.2021 - 28.11.2021

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Address: 56 Evergreen Drive, Portland, ME, United States, 04103

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

14.00 USD

P/E ratio

Dividend Yield

Current Year

+26 493 169 USD

Last Year

+17 471 669 USD

Current Quarter

+7 751 000 USD

Last Quarter

+6 011 573 USD

Current Year

+7 941 044 USD

Last Year

+4 396 284 USD

Current Quarter

+2 832 000 USD

Last Quarter

+1 583 554 USD

Key Figures ICCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 454 022 USD
Operating Margin TTM 13.27 %
Price to Earnings
Return On Assets TTM -1.73 %
PEG Ratio
Return On Equity TTM -8.21 %
Wall Street Target Price 14.00 USD
Revenue TTM 26 493 168 USD
Book Value 3.07 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 52.10 %
Dividend Yield
Gross Profit TTM 8 348 044 USD
Earnings per share -0.26 USD
Diluted Eps TTM -0.26 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY -63.40 %
Profit Margin -8.14 %

Dividend Analytics ICCC

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History ICCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:100
Payout Ratio
Last Split Date 25.07.1990

Stock Valuation ICCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.29
Price Sales TTM 1.86
Enterprise Value EBITDA 56.87
Price Book MRQ 1.79

Financials ICCC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ICCC

For 52 weeks

3.34 USD 5.82 USD
50 Day MA 5.10 USD
Shares Short Prior Month 13 234
200 Day MA 4.37 USD
Short Ratio 1.23
Shares Short 13 161
Short Percent 0.18 %